RS50537B - Derivati benzimidazola i njihovo korišćenje kao antagonista receptora a ii - Google Patents

Derivati benzimidazola i njihovo korišćenje kao antagonista receptora a ii

Info

Publication number
RS50537B
RS50537B RSP-2007/0448A RSP20070448A RS50537B RS 50537 B RS50537 B RS 50537B RS P20070448 A RSP20070448 A RS P20070448A RS 50537 B RS50537 B RS 50537B
Authority
RS
Serbia
Prior art keywords
receptor antagonist
benzimidazole derivative
formula
benzimidazole
derivative
Prior art date
Application number
RSP-2007/0448A
Other languages
English (en)
Inventor
Takanobu Kuroita
Hiroki Sakamoto
Mami Ojima
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34858222&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS50537(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of RS50537B publication Critical patent/RS50537B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Jedinjenja formule (I) gde je R1 grupa prerdstavljena formulom gde su R2, R3, R4, R5, R6, R7 i R8 svaki nezavisno atom vodonika ili C1-6 alkil, ili njegova so. Prijava sadrži još 17 patentnih zahteva.
RSP-2007/0448A 2004-02-25 2005-02-23 Derivati benzimidazola i njihovo korišćenje kao antagonista receptora a ii RS50537B (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004048928 2004-02-25
US11/031,057 US7157584B2 (en) 2004-02-25 2005-01-07 Benzimidazole derivative and use thereof
PCT/JP2005/003422 WO2005080384A2 (en) 2004-02-25 2005-02-23 Benzimidazole derivative and use as aii receptor antagonist

Publications (1)

Publication Number Publication Date
RS50537B true RS50537B (sr) 2010-05-07

Family

ID=34858222

Family Applications (3)

Application Number Title Priority Date Filing Date
RSP-2009/0484A RS51137B (sr) 2004-02-25 2005-02-23 Derivat benzimidazola i njegova upotreba kao antagonista receptora aii
RSP-2007/0448A RS50537B (sr) 2004-02-25 2005-02-23 Derivati benzimidazola i njihovo korišćenje kao antagonista receptora a ii
RS20120362A RS52376B (sr) 2004-02-25 2005-02-23 Derivati benzimidazola i njegova upotreba kao antagonista all receptora

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RSP-2009/0484A RS51137B (sr) 2004-02-25 2005-02-23 Derivat benzimidazola i njegova upotreba kao antagonista receptora aii

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20120362A RS52376B (sr) 2004-02-25 2005-02-23 Derivati benzimidazola i njegova upotreba kao antagonista all receptora

Country Status (33)

Country Link
US (3) US7157584B2 (sr)
EP (3) EP2119715B1 (sr)
JP (2) JP4256852B2 (sr)
KR (1) KR101080029B1 (sr)
CN (2) CN101381366B (sr)
AR (2) AR047972A1 (sr)
AT (2) ATE370136T1 (sr)
AU (1) AU2005214271B8 (sr)
BR (2) BR122012009489B8 (sr)
CA (1) CA2557538C (sr)
CY (5) CY1107008T1 (sr)
DE (3) DE602005016162D1 (sr)
DK (3) DK1857457T3 (sr)
ES (3) ES2293552T3 (sr)
HK (2) HK1098472A1 (sr)
HR (3) HRP20070510T3 (sr)
HU (1) HUS1200008I1 (sr)
IL (1) IL177533A (sr)
LU (1) LU91962I2 (sr)
MA (1) MA28478B1 (sr)
ME (2) ME01089B (sr)
MY (1) MY142807A (sr)
NL (1) NL300802I2 (sr)
NO (2) NO332344B1 (sr)
NZ (1) NZ549755A (sr)
PL (3) PL2119715T3 (sr)
PT (3) PT1857457E (sr)
RS (3) RS51137B (sr)
RU (2) RU2369608C2 (sr)
SI (3) SI1857457T1 (sr)
TW (1) TWI336702B (sr)
WO (1) WO2005080384A2 (sr)
ZA (1) ZA200607241B (sr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
US7795275B2 (en) 2004-12-24 2010-09-14 Uniquest Pty Limited Method of treatment or prophylaxis
JP4465469B2 (ja) * 2005-02-21 2010-05-19 国立大学法人佐賀大学 循環器病マーカーとしてのインターロイキン１３
CA2602624A1 (en) * 2005-03-30 2006-10-12 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use as angiotensin ii antagonist
WO2007097452A1 (ja) * 2006-02-27 2007-08-30 Takeda Pharmaceutical Company Limited 医薬用ブリスターパッケージ
US20090012132A1 (en) * 2006-02-27 2009-01-08 Takeda Pharmaceutical Company Limited Pharmaceutical Package
EP1996183A4 (en) * 2006-03-20 2010-04-14 Spinifex Pharm Pty Ltd METHOD FOR THE TREATMENT OR PROPHYLAXIS OF INFLAMMATORY PAIN
ES2381507T3 (es) * 2006-09-25 2012-05-28 Takeda Pharmaceutical Company Limited Envase medicinal
BRPI0809522A2 (pt) * 2007-03-28 2014-10-14 Takeda Pharmaceutical Composição farmacêutica sólida, métodos para estabilizar um composto, e para melhorar dissolução de um composto, e, uso de um agente de controle de ph.
JP2009062296A (ja) * 2007-09-05 2009-03-26 Fujifilm Corp カルボン酸エステル化合物の製造方法
JP5554699B2 (ja) * 2008-03-13 2014-07-23 第一三共株式会社 オルメサルタンメドキソミルを含む製剤の溶出性の改善
UY32017A (es) 2008-07-31 2010-02-26 Takeda Pharmaceutical Composición farmacéutica sólida
UY32126A (es) 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
CN102264228A (zh) * 2008-10-22 2011-11-30 默沙东公司 用于抗糖尿病药的新的环状苯并咪唑衍生物
WO2010075347A2 (en) 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
KR101931209B1 (ko) 2010-05-11 2018-12-20 얀센 파마슈티카 엔.브이. Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형
WO2012090043A1 (en) 2010-12-29 2012-07-05 Jubilant Life Sciences Limited Novel solid state forms of azilsartan medoxomil and preparation thereof
CA2824316C (en) 2011-01-20 2020-07-07 Jiangsu Hansoh Pharmaceutical Co., Ltd. Organic amine salts of azilsartan, preparation method and use thereof
EP2673274B1 (en) 2011-02-08 2019-07-17 Jubilant Generics Limited An improved process for the preparation of azilsartan medoxomil
CN102138899B (zh) * 2011-03-18 2013-08-21 海南本创医药科技有限公司 阿齐沙坦酯脂质体固体制剂
AU2012241897C1 (en) 2011-04-13 2017-05-11 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
CN102827153B (zh) * 2011-06-14 2016-10-05 江苏豪森药业集团有限公司 阿齐沙坦的晶型及其制备方法
CN102351853B (zh) * 2011-08-29 2014-03-12 石药集团欧意药业有限公司 一种阿齐沙坦酯化合物、制备方法及其药物组合物
WO2013042067A1 (en) 2011-09-20 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of potassium salt of azilsartan medoxomil
WO2013042066A1 (en) 2011-09-20 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of azilsartan medoxomil
BR112014014527A2 (pt) 2011-12-15 2017-06-13 Takeda Pharmaceuticals Usa Inc combinações de azilsartan e clorotalidona para tratar hipertensão em pacientes negros
WO2013088384A2 (en) 2011-12-15 2013-06-20 Jubilant Life Sciences Limited Solid state forms of azilsartan and azilsartan medoxomil monopotassium and preparation thereof
US9403811B2 (en) 2012-01-14 2016-08-02 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan medoxomil potassium and preparation and uses thereof
US20150011774A1 (en) * 2012-02-02 2015-01-08 Ranbaxy Laboratories Limited Process for the preparation of azilsartan medoxomil or pharmaceutically acceptable salts thereof
WO2013124748A1 (en) * 2012-02-20 2013-08-29 Alembic Pharmaceuticals Limited Novel polymorphs of azilsartan medoxomil potassium
CZ2012274A3 (cs) * 2012-04-19 2013-10-30 Zentiva, K.S. Zpusob prípravy vysoce cisté draselné soli azilsartanu medoxomilu
WO2013186792A2 (en) * 2012-06-11 2013-12-19 Msn Laboratories Limited Process for the preparation of (5-methyl-2-oxo-l,3-dioxoi-4-vl)methvl 2- ethoxv-l-{[2'-(5-oxo-4,5-dihvdro-l,2,4-oxadiazol-3-vl)biphenyi-4-vl]methyl}- lh-benzimidazole-7-carboxyiate and its salts
EP2870151A4 (en) * 2012-07-09 2016-03-23 Hetero Research Foundation NEW POLYMORPHIC AZILSARTAN
WO2014020381A1 (en) * 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited Novel crystalline form of azilsartan medoxomil potassium
CA2890961A1 (en) 2012-08-27 2014-03-06 Hetero Research Foundation Novel polymorphs of azilsartan medoxomil
WO2014049512A2 (en) 2012-09-26 2014-04-03 Lupin Limited Novel process for preparation of azilsartan medoxomil
CZ305318B6 (cs) * 2012-09-26 2015-07-29 Zentiva, K.S. Způsob přípravy vysoce čisté draselné soli azilsartanu medoxomilu
CN103709154B (zh) * 2012-09-28 2016-06-15 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
IN2015DN03074A (sr) * 2012-10-09 2015-10-02 Avery Dennison Corp
CN103910720A (zh) * 2013-01-07 2014-07-09 广东东阳光药业有限公司 阿齐沙坦酯的新晶型及其制备方法
CN105153141B (zh) * 2013-02-04 2018-09-25 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
JP6281735B2 (ja) * 2013-03-19 2018-02-21 トーアエイヨー株式会社 急性心不全治療薬の評価方法、及び、急性心不全モデルの作製方法
RU2535005C1 (ru) * 2013-06-11 2014-12-10 Николай Андреевич Козлов Способ лечения грыж межпозвонковых дисков у собак
RU2535004C1 (ru) * 2013-06-11 2014-12-10 Николай Андреевич Козлов Способ лечения грыж межпозвонковых дисков у собак
CN105949182B (zh) * 2013-10-12 2019-03-19 杭州领业医药科技有限公司 阿齐沙坦酯的晶型及其制备方法
CN104812752B (zh) * 2013-10-12 2016-09-28 杭州领业医药科技有限公司 阿齐沙坦酯的晶型及其制备方法
CN104774196B (zh) * 2014-01-09 2017-11-10 武汉朗来科技发展有限公司 一种苯并咪唑衍生物的制备方法
CN104774197B (zh) * 2014-01-09 2017-11-17 武汉朗来科技发展有限公司 一种苯并咪唑衍生物的制备方法
CN105079815A (zh) * 2014-04-30 2015-11-25 广东东阳光药业有限公司 一种阿齐沙坦酯钾组合物及其制备方法
CN104016974A (zh) * 2014-06-24 2014-09-03 浙江天宇药业股份有限公司 阿齐沙坦酯中间体及其合成方法、阿齐沙坦酯的合成方法
CZ2014702A3 (cs) 2014-10-15 2016-04-27 Zentiva, K.S. Způsob přípravy vysoce čistého azilsartanu
CN105622595A (zh) * 2014-11-21 2016-06-01 重庆朗天制药有限公司 一种阿奇沙坦酯钾盐及其中间体新的制备方法
CN105753854A (zh) * 2014-12-16 2016-07-13 重庆朗天制药有限公司 一种阿齐沙坦酯钾盐的新制备方法
WO2016145622A1 (zh) 2015-03-18 2016-09-22 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
CN106032378B (zh) * 2015-03-20 2019-10-25 武汉启瑞药业有限公司 新型arb化合物及其用途
CN104803998B (zh) * 2015-03-26 2017-08-25 晋江市托美汀生物科技有限公司 一种降低杂质含量的方法
JP2018521077A (ja) * 2015-07-29 2018-08-02 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 糖尿病性腎症を治療するためのｐｄｅ４阻害剤
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN109071519A (zh) * 2016-01-28 2018-12-21 株式会社德山 阿齐沙坦及其制造方法
JP6856365B2 (ja) * 2016-11-30 2021-04-07 株式会社トクヤマ アジルサルタンの製造方法
CN105628824B (zh) * 2016-03-06 2017-10-17 江苏正大清江制药有限公司 一种高效液相色谱法测定阿齐沙坦原料中有关物质的方法
CN107400122B (zh) 2016-05-20 2020-10-23 武汉朗来科技发展有限公司 化合物及其制备方法、组合物和应用
CN105770876B (zh) * 2016-05-30 2019-09-10 广东天普生化医药股份有限公司 乌司他丁在制备治疗慢性***炎药物中的用途
RU2623082C1 (ru) * 2016-07-11 2017-06-21 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ коррекции артериальной ригидности у больных ревматоидным артритом
EP3461822B1 (en) * 2016-07-11 2022-11-02 Wuhan LL Science And Technology Development Co., Ltd. Crystalline form of chemical compound, and preparation method, composition, and application thereof
RU2634272C1 (ru) * 2016-08-10 2017-10-24 Закрытое акционерное общество "Санкт-Петербургский институт фармации" Композиция с дезамино-аргинин-вазотоцином для парентерального введения и способ её получения
CN106074416A (zh) * 2016-08-30 2016-11-09 佛山市弘泰药物研发有限公司 一种阿齐沙坦酯钾盐分散片的制备方法
CN109803657B (zh) * 2016-10-08 2022-07-29 武汉朗来科技发展有限公司 药物组合物
WO2019130277A1 (en) 2017-12-30 2019-07-04 Lupin Limited Pharmaceutical formulations of azilsartan medoxomil
CN110237071B (zh) * 2018-03-09 2022-03-22 武汉朗来科技发展有限公司 药物制剂及其应用
CN110237072B (zh) * 2018-03-09 2022-03-25 武汉朗来科技发展有限公司 药物组合物的制备方法
CN117542473A (zh) 2018-06-14 2024-02-09 阿斯利康(英国)有限公司 用血管紧张素ii受体阻滞剂医药组合物治疗高血压的方法
US11417416B2 (en) * 2018-06-14 2022-08-16 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
WO2020101450A1 (ko) 2018-11-16 2020-05-22 엠에프씨 주식회사 아질사르탄 유도체 화합물, 이의 중간체, 이의 제조방법 및 이를 포함하는 조성물
JPWO2020166710A1 (ja) 2019-02-15 2021-12-16 国立大学法人東北大学 １，３−ジオキソラン誘導体
KR102220011B1 (ko) 2020-05-15 2021-02-25 대봉엘에스 주식회사 친환경 용매를 이용한 아질사탄의 제조방법 및 이에 관한 핵심 중간체 화합물
CN113912580B (zh) * 2021-11-03 2023-06-02 瑞孚信江苏药业股份有限公司 一种纯化4-(羟甲基)-5-甲基-[1,3]二氧杂环戊烯-2-酮的方法
CA3231724A1 (en) 2021-12-28 2023-07-06 Alchemedicine, Inc. Compound, angiotensin ii type 1 receptor antagonist and pharmaceutical composition
KR20240039252A (ko) 2022-09-19 2024-03-26 대봉엘에스 주식회사 안지오텐신 ⅱ 길항제로서의 아질사르탄 디시클로헥실아민 및 이를 유효성분으로 하는 심혈관질환 치료 또는 예방용 약학적 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62290071A (ja) 1986-06-09 1987-12-16 Matsushita Electric Ind Co Ltd 有機電解質二次電池
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
IS1756B (is) 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
RU2117668C1 (ru) * 1991-10-23 1998-08-20 Эйсаи Ко., Лтд. Производное оксазолидона или его фармакологически приемлемые соли, фармацевтическая композиция, способ лечения
US5310929A (en) 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
US5605919A (en) * 1993-02-26 1997-02-25 Takeda Chemical Industries, Ltd. Treatment for viral diseases
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5610314A (en) 1995-04-03 1997-03-11 Bristol-Myers Squibb Company Process for preparing dioxolenone derivatives used for making prodrug esters and intermediates
KR100866820B1 (ko) 2000-07-13 2008-11-04 다케다 야쿠힌 고교 가부시키가이샤 지질 풍부 플라크 퇴축제
AU2002349673A1 (en) 2001-12-03 2003-06-17 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
KR20040081123A (ko) 2002-01-11 2004-09-20 다케다 야쿠힌 고교 가부시키가이샤 쿠마린 유도체, 이의 제조 방법 및 용도
CA2507026A1 (en) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Imidazole derivatives, their production and use
US6972258B2 (en) * 2003-08-04 2005-12-06 Taiwan Semiconductor Manufacturing Co., Ltd. Method for selectively controlling damascene CD bias
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
JP4364171B2 (ja) 2005-07-15 2009-11-11 本田技研工業株式会社 自動車用ドアチェッカ
UA58542U (ru) * 2010-12-16 2011-04-11 Леонид Борисович Борейко Способ фиксирования эвакуационной машины во время вытягивания застрявшей тяжелой машины

Also Published As

Publication number Publication date
CY2012015I2 (el) 2016-12-14
US7572920B2 (en) 2009-08-11
MY142807A (en) 2011-01-14
RU2009115498A (ru) 2010-10-27
LU91962I2 (fr) 2012-05-21
EP1718641A2 (en) 2006-11-08
IL177533A0 (en) 2006-12-10
WO2005080384A2 (en) 2005-09-01
EP1718641B1 (en) 2007-08-15
CN1946717A (zh) 2007-04-11
HRP20070510T3 (en) 2007-12-31
CN101381366A (zh) 2009-03-11
PL1857457T3 (pl) 2009-12-31
CY1107008T1 (el) 2012-09-26
NZ549755A (en) 2009-04-30
AU2005214271B8 (en) 2011-03-03
AR094588A2 (es) 2015-08-12
MA28478B1 (fr) 2007-03-01
BRPI0507984B8 (pt) 2023-03-21
RU2501798C2 (ru) 2013-12-20
SI1857457T1 (sl) 2010-01-29
CY2012016I1 (el) 2016-12-14
TW200530227A (en) 2005-09-16
ES2293552T3 (es) 2008-03-16
CY1109610T1 (el) 2014-08-13
ME01643B (me) 2010-05-07
CY2012015I1 (el) 2016-12-14
HRP20090593T1 (hr) 2010-03-31
CN101381366B (zh) 2011-06-15
CY2012016I2 (el) 2016-12-14
ES2331209T3 (es) 2009-12-23
TWI336702B (en) 2011-02-01
PL2119715T3 (pl) 2012-10-31
DE602005002030D1 (de) 2007-09-27
RU2369608C2 (ru) 2009-10-10
WO2005080384A3 (en) 2006-09-28
JP2005272451A (ja) 2005-10-06
EP2119715B1 (en) 2012-05-30
PT1718641E (pt) 2007-11-15
NO332344B1 (no) 2012-09-03
HUS1200008I1 (hu) 2017-06-28
BR122012009489B8 (pt) 2023-03-21
PL1718641T3 (pl) 2008-01-31
US7157584B2 (en) 2007-01-02
AU2005214271A2 (en) 2005-09-01
HK1098472A1 (en) 2007-07-20
DE602005016162D1 (de) 2009-10-01
SI2119715T1 (sl) 2012-10-30
AU2005214271B2 (en) 2011-02-24
JP4256852B2 (ja) 2009-04-22
HRP20120667T2 (hr) 2012-11-30
ES2388945T3 (es) 2012-10-22
EP2119715A1 (en) 2009-11-18
HK1115118A1 (en) 2008-11-21
US20050187269A1 (en) 2005-08-25
BRPI0507984B1 (pt) 2018-07-03
HRP20120667T1 (en) 2012-09-30
RS51137B (sr) 2010-10-31
DE122012000018I1 (de) 2012-06-06
EP1857457A3 (en) 2007-12-05
DK1718641T3 (da) 2007-12-17
ATE370136T1 (de) 2007-09-15
BR122012009489B1 (pt) 2019-02-19
NO2012017I2 (no) 2012-11-09
CA2557538A1 (en) 2005-09-01
WO2005080384A9 (en) 2006-11-30
DE602005002030T2 (de) 2008-05-08
US20060281795A1 (en) 2006-12-14
RS52376B (sr) 2012-12-31
US7875637B2 (en) 2011-01-25
JP2009137974A (ja) 2009-06-25
KR20070020411A (ko) 2007-02-21
CN100503605C (zh) 2009-06-24
NO20064251L (no) 2006-11-22
ME01089B (me) 2013-03-20
ATE440095T1 (de) 2009-09-15
NL300802I2 (sr) 2016-05-18
NO2012017I1 (no) 2012-11-26
SI1718641T1 (sl) 2007-12-31
IL177533A (en) 2010-12-30
BRPI0507984A (pt) 2007-07-24
EP1857457B1 (en) 2009-08-19
PT1857457E (pt) 2009-09-23
DK1857457T3 (da) 2009-12-21
RU2006133898A (ru) 2008-03-27
DK2119715T3 (da) 2012-09-10
EP1857457A2 (en) 2007-11-21
CY1113084T1 (el) 2016-04-13
PT2119715E (pt) 2012-09-03
AU2005214271A1 (en) 2005-09-01
KR101080029B1 (ko) 2011-11-04
ZA200607241B (en) 2008-04-30
US20090270464A1 (en) 2009-10-29
CA2557538C (en) 2010-08-17
AR047972A1 (es) 2006-03-15

Similar Documents

Publication Publication Date Title
RS50537B (sr) Derivati benzimidazola i njihovo korišćenje kao antagonista receptora a ii
ME01421B (me) 5-supstituisani derivati kinazolinona kao protivtumorska sredstva
ME00004B (me) Derivati pirimidina
RS52119B (sr) 4-fenilamino-hinazolin-6-il-amidi
CY1113029T1 (el) Παραγωγα αζαδικυκλο [3.1.0] εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
RS52261B (sr) Amidofenoksi indazoli kao korisni inhibitori c-met-a
RS52307B (sr) Kondenzovana ciklična jedinjenja
RS53839B1 (sr) Spirocikli kao inhibitori 11-beta hidroksisteroid dehidrogenaze tipa 1
SMT201300085B (it) Composti di pirrolo
ATE506354T1 (de) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
MY153910A (en) BICYCLIC y-AMINO ACID DERIVATIVE
CY1112914T1 (el) Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
AR057894A1 (es) Derivados de tiofeno
ATE376833T1 (de) Chinazolinon-derivate als vanilloid-antagonisten
RS50519B (sr) Supstituisani derivati 8'-piri(mi)dinil-dihidrospiro- /cikloalkilamin/-pirimido/1,2-a/pirimidin-6-ona
RS51545B (sr) Tiazol pirazolopiramidini kao antagonisti crf1 receptora
HRP20050390A2 (en) Substituted benzoxazinones and uses thereof
ATE340795T1 (de) Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
NO20071922L (no) Indazoler, benzisokazoler og benzinsotiazoler og anvendelse derav som ostrogene midler
EA200970793A1 (ru) Модуляторы рецепторов, активируемых пролифераторами пероксисом
RS53414B (sr) Derivati pirazinooksazepina
DE602005007064D1 (de) Chromanderivate und ihre verwendung als liganden des 5-ht-rezeptors